A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil

Name: A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil
SKU: 8007
Availability: InStock

$0.00

A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil

By Robert Risinger, Marjie Hard, Peter J. Weiden

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 47 No. 3 Articles - 2017 Tags: antipsychotic-agents, aripiprazole, aripiprazole-lauroxil, marjie-hard, peter-j-weiden, prodrugs, psychomotor-agitation, psychopharmacology, robert-risinger, schizophrenia, weight-gain

Description

Description

A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil

By Robert Risinger, Marjie Hard, Peter J. Weiden

26-34_PB-47-3-2017_Risinger

A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil

Description

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Larry Alphs, MD, PhD: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Agomelatine for Depression in Schizophrenia by Jochen Mutschler

Title

A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil

Description

Related products

Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia

Larry Alphs, MD, PhD: Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Agomelatine for Depression in Schizophrenia by Jochen Mutschler

Title